Spyre Therapeutics (SYRE) Preferred Shares (2015 - 2026)

Spyre Therapeutics' Preferred Shares history runs 4 years deep, the most recent figure standing at $146.4 million for Q1 2026.

• Quarterly Preferred Shares changed N/A year-over-year to $146.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.4 million (changed N/A YoY) and the FY2025 annual result came in at $9.4 million, changed 0.0% from the prior year.
• Preferred Shares was $146.4 million for Q1 2026 at Spyre Therapeutics, up from $9.4 million in the prior quarter.
• Across five years, Preferred Shares topped out at $184.9 million in Q1 2024 and bottomed at $9.4 million in Q4 2024.
• A 3-year average of $117.0 million and a median of $146.4 million in 2024 frame the typical range for Preferred Shares.
• Peak annual rise in Preferred Shares reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Spyre Therapeutics' Preferred Shares stood at $9.4 million in 2024, then changed by 0.0% to $9.4 million in 2025, then soared by 1458.54% to $146.4 million in 2026.
• Business Quant data shows SYRE's Preferred Shares at $146.4 million in Q1 2026, $9.4 million in Q4 2025, and $146.4 million in Q3 2025.